Envista Holdings Corporation (NYSE:NVST) Given Consensus Rating of “Hold” by Brokerages

Shares of Envista Holdings Corporation (NYSE:NVST) have earned a consensus recommendation of “Hold” from the sixteen ratings firms that are covering the stock, MarketBeat.com reports. Ten research analysts have rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $28.5385.

A number of analysts recently weighed in on NVST shares. Morgan Stanley lifted their price target on Envista from $19.00 to $21.00 and gave the company an “equal weight” rating in a research note on Friday, April 24th. Wall Street Zen cut Envista from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 9th. JPMorgan Chase & Co. raised their target price on Envista from $26.00 to $29.00 and gave the company a “neutral” rating in a report on Thursday, May 7th. Robert W. Baird boosted their target price on shares of Envista from $30.00 to $31.00 and gave the stock an “outperform” rating in a research report on Thursday, May 7th. Finally, Evercore restated an “outperform” rating and set a $33.00 target price on shares of Envista in a research report on Thursday, May 7th.

Envista Trading Up 0.0%

NYSE NVST opened at $25.75 on Friday. The company has a quick ratio of 2.06, a current ratio of 2.44 and a debt-to-equity ratio of 0.47. The stock has a market capitalization of $4.19 billion, a P/E ratio of 62.80, a P/E/G ratio of 1.46 and a beta of 0.86. Envista has a 52-week low of $18.77 and a 52-week high of $30.42. The firm has a 50-day moving average price of $24.84 and a 200 day moving average price of $25.42.

Envista (NYSE:NVST) last announced its quarterly earnings data on Wednesday, May 6th. The company reported $0.36 earnings per share for the quarter, beating analysts’ consensus estimates of $0.31 by $0.05. Envista had a return on equity of 7.11% and a net margin of 2.41%.The company had revenue of $705.50 million for the quarter, compared to analyst estimates of $680.03 million. During the same quarter in the previous year, the company earned $0.24 EPS. The firm’s revenue for the quarter was up 14.4% compared to the same quarter last year. Envista has set its FY 2026 guidance at 1.350-1.450 EPS. Equities research analysts expect that Envista will post 1.42 EPS for the current year.

Hedge Funds Weigh In On Envista

Several hedge funds and other institutional investors have recently bought and sold shares of NVST. Millennium Management LLC grew its holdings in Envista by 1,442.7% in the fourth quarter. Millennium Management LLC now owns 2,420,615 shares of the company’s stock valued at $52,552,000 after purchasing an additional 2,263,712 shares during the last quarter. Holocene Advisors LP purchased a new position in shares of Envista in the second quarter valued at $43,936,000. Arrowstreet Capital Limited Partnership raised its stake in shares of Envista by 341.5% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 2,858,293 shares of the company’s stock worth $72,515,000 after buying an additional 2,210,847 shares during the last quarter. Norges Bank acquired a new position in shares of Envista during the 4th quarter worth $45,113,000. Finally, Alliancebernstein L.P. boosted its position in shares of Envista by 34.0% in the 2nd quarter. Alliancebernstein L.P. now owns 6,098,445 shares of the company’s stock worth $119,164,000 after buying an additional 1,547,656 shares in the last quarter.

Envista Company Profile

Envista Holdings Corporation is a global dental products company that develops, manufactures and markets a broad portfolio of dental consumables, equipment and technology solutions. Headquartered in Brea, California, Envista serves dental practitioners, specialists and laboratories in more than 150 countries. The company’s offerings span implant, orthodontic, endodontic and restorative product lines as well as digital imaging systems and practice management software.

Envista’s product brands include Nobel Biocare for dental implants and restorative solutions, Ormco for orthodontic appliances and treatment systems, Kerr for restorative and endodontic materials, KaVo for dental imaging and handpieces, and Vista for surgical drills and instruments.